Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model

Bone

Volumn 20, Issue 1, 1997, Pages 31-39

  Ke, H Z ^a   Chen, H K ^b   Simmons, H A ^a   Qi, H ^a   Crawford, D T ^a   Pirie, C M ^a   Chidsey Frink, K L ^a   Ma, Y F ^b   Jee, W S S ^b   Thompson, D D ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Droloxifene; Estrogen; Osteoporosis; Serum cholesterol; Tamoxifen; Uterine histology

Indexed keywords

CHOLESTEROL; DROLOXIFENE; ESTROGEN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CANCELLOUS BONE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; LUMBAR VERTEBRA; METAPHYSIS; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RAT; STROMA; TIBIA; UTERUS WEIGHT; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BONE DENSITY; BONE RESORPTION; CHOLESTEROL; DENSITOMETRY, X-RAY; DISEASE MODELS, ANIMAL; ESTRADIOL CONGENERS; ESTROGEN ANTAGONISTS; ETHINYL ESTRADIOL; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TIBIA; UTERUS; WEIGHT GAIN;

EID: 0031013929     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00313-4     Document Type: Article

References (50)

1. Bagdade, J. D., Wolter, J., Subbaiah, P. V., and Ryan, W. Effects of tamoxifen treatment on plasma lipid and lipoprotein lipid composition. J Clin Endocrinol Metab 70:1132-1135; 1990.
2. Berry, M., Metzger, D., and Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818; 1990.
3. Breitbach, G. P., Reister, C., Droege, H., and Basiert, G. Pharmacokinetics of droloxifene in comparison with tamoxifen. Onkologie 17(Suppl. 1):49-53; 1994.
4. Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., and Cummings, S. R. Estrogen replacement therapy and fractures in older women. Ann Int Med 122:9-16; 1995.
5. Chen, H. K., Ke, H. Z., Jee, W. S. S., Ma, Y. F., Pirie, C. M., Simmons, H. A., and Thompson, D. D. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: A dual-energy x-ray absorptiometric and histomorphometric study. J Bone Miner Res 10:1256-1262; 1995.
6. Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., and Speizer, F. E. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 332:1589-1593; 1995.
7. Cummings, S. R., Rubin, S. M., and Black, D. The future of hip fractures in the United States: Number, costs, and potential effects of postmenopausal estrogen. Clin Orthop 252:163-166; 1990.
8. Eppenberger, U., Wosikowski, K., and Kung, W. 1991. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol (CCT) 14 (Suppl. 2):S5-S14; 1991.
9. Evans, G. L. and Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 17 (Suppl. 4):181S-190S; 1995.
10. Frost, H. M. and Jee, W. S. S. On the rat model of human osteopenias and osteoporosis. Bone Miner 18:227-236; 1992.
11. Gery, A. B., Stapleton, J. P., Evans, M. C., and Reid, I. R. The effects of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80:3191-3195; 1995.
12. Grasser, W. A., Pan, L. C., Thompson, D. D., and Paralkar, V. M. A common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cellular Biochem. In press.
13. Greaves, P., Goonetilleke, R., Numm, G., Topham, J., and Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53 (Suppl. 1):3919-3924; 1993.
14. Grill, H. J. and Follow, K. Pharmacokinetic of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol (CCT) 14(Suppl. 2):S21-S29; 1991.
15. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541; 1993.
16. Hung, H. T. and Pollak, M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53:5585-5588; 1993.
17. Jordan, V. C. and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocrin Rev 11:578-610; 1990.
18. Kalu, D. N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192; 1991.
19. Kalu, D. N., Salerno, E., Liu, C. C., Echon, R., Ray, M., Garza-Zapata, M., and Hollis, B. W. A comparative study of the actions of tamoxifen, estrogen, and progesterone in the ovariectomized rat. Bone Miner 15:109-124; 1991.
20. Ke, H. Z., Simmons, H. A., Pirie, C. M., Crawford, D. T., and Thompson, D. D. Droloxifene, a new estrogen antagonist/agonist prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441; 1995.
21. Ke, H. Z., Chen, H. K., Qi, H., Pirie, C. M., Simmons, H. A., Ma, Y. F., Jee, W. S. S., and Thompson, D. D. Effects of droloxifene on prevention of bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 17:491-496; 1995.
22. Kedar, R. P., Bourne, T. H., Powles, T. J., Collins, W. P., Ashley, S. E., and Cosgrove, D. O. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321; 1994.
23. Kenny, A. M., Prestwood, K. M., Pilbeam, C. C., and Raisz, L. G. The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80:3287-3291; 1995.
24. Kristensen, B., Ejlertsen, B., Dalgaard, P., Larsen, L., Holmegaard, S. N., Transbol, I., and Mouridsen, H. T. Tamoxifen and bone metabolism in post-menopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12:992-997; 1994.
25. Lahti, E., Guillermo, B., and Kauppila, A. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660-664; 1993.
26. Lindsay, R. and Cosman, F. Primary osteoporosis. Coe, F. L. and Favus, M. J., Eds. Disorder of Bone and Mineral Metabolism. New York: Raven; 1992; 831-888.
27. Lobo, R. A. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173:982-990; 1995.
28. Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., and DeMets, D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864; 1991.
29. Love, R. R., Bardon, H. S., Mazess, R. B., Epstein, S., and Chappell, R. J. Effects of tamoxifen on lumbar spine bone mineral density in postmenopausal women after five years. Arch Intern Med 154:2585-2588; 1994.
30. Love, R. R., Mazes, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and DeMets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Eng J Med 326:852-856; 1991.
31. Maxim, P., Ettinger, B., and Spitalny, G. M. Fracture protection provided by long-term estrogen treatment. Osteoporosis Int 5:23-29; 1995.
32. Moon, L. Y., Wakley, G. K., and Turner, R. T. Dose-dependent effects of tamoxifen on long bones of growing rats: Influence of ovarian status. Endocrinology 129:1568-1574; 1991.
33. Neter, J., Wasserman, W., and Ahitmore, G. A. Applied Statistics. Boston: Allyn and Bacon; 1982; 544-572.
34. Osteoporosis. Berg, R. L. and Casell, J. S., Eds. The Second Fifty Years: Promoting Health and Preventing Disability. Washington, D.C.: National Academy; 1990; 76-100.
35. Paganini-Hill, A. The benefits of estrogen replacement therapy on oral health. Arch Intern Med 155:2325-2329; 1995.
36. Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610; 1987.
37. Petersen, D. N., Thiede, M. A., Crawford, D. T., Ke, H. Z., and Thompson, D. D. Droloxifene effects on IGF binding protein 3 may modulate its lack of uterotrophic responses. J Bone Miner Res 10(Suppl.): S390; 1995.
38. Dahme, E. G. and Rattel, B. Hepatocarcinogenicity of tamoxifen but not droloxifene in rats. J Cancer Res Clin Oncol 118(Suppl.): R172; 1992.
39. Riggs, B. L. and Melton, L. J., III. Involutional osteoporosis. N Eng J Med 314:1676-1686; 1986.
40. Shull, J. D., Beams, F. E., Baldwin, T. M., Gilehrist, C. A., and Hebek, M. J. The estrogenic and antiestrogenic properties of tamoxifen in GH4C1 pituitary tumor cells are gene specific. Mol Endocrinol 6:529-535; 1992.
41. Stampfer, M. J. and Colditz, G. A. Estrogen replacement therapy and coronary heart diseases: A quantative assessment of the epidemiologic evidence. Prev Med 20:47-63; 1991.
42. Tanaka, Y., Sekiguchi, M., Sawamoto, T., Hata, T., Esumi, Y., Sugai, S., and Ninomiya, S. Pharmacokinetic of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal women. Eur J Drug Metab Pharmacokinet 19:47-58; 1994.
43. Turner, R. T., Wakley, G. K., Hannon, K. S., and Bell, N. H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2:449-456; 1987.
44. Turner, R. T., Wakley, G. K., Hannon, K. S., and Bell, N. H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122:1146-1150; 1988.
45. Wakley, G. K., Baum, B. L., Hannon, K. S., and Turner, R. T. The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: A histomorphometric study. Calcif Tissue Int 43:383-388; 1988.
46. Ward, R. L., Morgan, G., Dalley, D., and Kelly, P. J. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22:87-94; 1993.
47. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hower, A., and Phillips, D. H. I. Genotoxic potential of tamoxifen and analogues in female Ficsher F344/N rats, DBA/2 and C57/BL/6 mice and human MCL-5 cells. Carcinogenesis 13:2197-2203; 1992.
48. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., and Kaltenberg, O. P., The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317; 1993.
49. Wright, C. D. P., Garrahan, N. J., Stanton, M., Gazet, J.-C., Mansell, R. E., and Compston, J. E. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J Bone Miner Res 9:153-159; 1994.
50. Wronski, T. J. and Yen, C.-F. The ovariectomized rat model as an animal model for postmenopausal bone loss. Cells Materials (Suppl. 1):69-74; 1991.